If Joe Biden ends up slinking his way into the White House — with an escort, of course, because he doesn’t know where he is or what he’s saying half the time — we can be certain of a few things.
One, he will reverse some of the best Executive Branch policies President Donald Trump enacted that were good for American workers, American companies and American liberty.
Two, he’ll stop construction on the massively effective border wall Trump promised along the southwest border (he’s already said he would).
Three, he’ll pander to the left-wing AOC mob because that is the direction his party is moving.
And four, with the help of the garbage media, Biden will take credit for one Trump triumph after another, including the rapid, successful development of a COVID-19 vaccine.
Granted, we’re not huge fans of vaccines around here and our long-time readers know that — and why. Regardless of what happens with the vaccine, under a Biden nightmare, prepare for perpetual nationwide mask mandates, additional lockdowns, and other restrictions on our liberties and life (though it should be noted that Trump did not shut down a single state, city, or county; he left those decisions to state and local leaders, which is a little concept our founders called federalism).
Speaking of coronavirus, you may have heard that Pfizer announced this week that it had developed a COVID-19 vaccine that successfully blocks infection 90 percent of the time. And it was developed in record time, under Trump’s Operation Warp Speed program; the fastest an anti-viral vaccine has ever been developed.
But for some reason, Pfizer didn’t make the announcement until after it appeared that Trump lost the presidential election.
The question is…why?
Even Stat News is questioning the timing of the big pharma giant's announcement:
In their announcement of the results, Pfizer and BioNTech revealed a surprise. The companies said they had decided not to conduct the 32-case analysis “after a discussion with the FDA.” Instead, they planned to conduct the analysis after 62 cases. But by the time the plan had been formalized, there had been 94 cases of Covid-19 in the study.
It’s not known how many were in the vaccine arm, but it would have to be nine or fewer. Gruber said that Pfizer and BioNTech had decided in late October that they wanted to drop the 32-case interim analysis. At that time, the companies decided to stop having their lab confirm cases of Covid-19 in the study, instead leaving samples in storage. The FDA was aware of this decision. Discussions between the agency and the companies concluded, and testing began this past Wednesday.
Got that? The original plan was to do a 32-case analysis, which grew to 62; the results were supposed to be announced in October. But for some reason Pfizer expanded the case study to 94, thus delaying the announcement of the results (and recall, Trump repeatedly said over the summer that he expected that a vaccine would be developed before the Nov. 3 election).
Why?
“This means that the statistical strength of the result is likely far stronger than was initially expected. It also means that if Pfizer had held to the original plan, the data would likely have been available in October, as its CEO, Albert Bourla, had initially predicted,” Stat News reported.
Did the FDA and Pfizer conspire to delay the announcement of this breakthrough treatment until after Election Day? That is not at all beyond the realm of possibility, especially given all of the wild accusations and charges Democrats and left-wing media sycophants (and their supporters) have leveled at Trump, blaming him and not China for COVID-19 and claiming that any vaccine he ordered developed would automatically be risky.
Something stinks here, and considering the extent Democrat operatives have gone to steal this election, we don’t put anything past them, including delaying the announcement of a COVID-19 vaccine that definitely would have been beneficial to the president ahead of in-person voting Nov. 3.
Stay up with the latest vaccine data and research at Vaccine.news.
Sources include:
Please contact us for more information.